Physician profile
Babak Danesh
NPI 1306823786
$2,218.55
in general payments reported to CMS, 2019-2025
20 companies · $123 in 2025
The $123 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $312 · 2020: $364 · 2021: $308 · 2022: $401 · 2023: $382 · 2024: $327 · 2025: $123.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $833.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $832.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $611.41 | 2019-2020 | |
| Abbvie INC. | $516.40 | 2020-2025 | Skyrizi, Rinvoq |
| Pfizer INC. | $218.33 | 2024-2025 | |
| Nestle Healthcare Nutrition INC. | $181.17 | 2020-2023 | |
| Intercept Pharmaceuticals, INC. | $169.75 | 2022-2023 | Ocaliva |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $78.95 | 2021-2022 | |
| Janssen Biotech, INC. | $61.75 | 2022 | |
| Genzyme Corporation | $50.40 | 2023-2025 | |
| Organon LLC | $48.27 | 2023-2025 | Renflexis, Hadlima |
| Daiichi Sankyo INC. | $48.25 | 2024 | Injectafer |
| Redhill Biopharma INC. | $36.77 | 2021-2022 | |
| Ferring Pharmaceuticals INC. | $32.02 | 2021 | |
| Ardelyx, INC. | $30.17 | 2023 | Ibsrela |
| Axonics, INC. | $25.03 | 2021 | |
| Janssen Pharmaceuticals, INC | $22.58 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $20.47 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.03 | 2023 | Cyltezo |
| Merck Sharp & Dohme LLC | $18.59 | 2021 | |
| Evoke Pharma, INC. | $14.93 | 2023 | Gimoti |
| Celgene Corporation | $13.28 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Babak Danesh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.